Effect of Supplementation of a Butyrate-Based Formula in Individuals with Liver Steatosis and Metabolic Syndrome: A Randomized Double-Blind Placebo-Controlled Clinical Trial

被引:3
|
作者
Fogacci, Federica [1 ]
Giovannini, Marina [1 ]
Di Micoli, Valentina [1 ]
Grandi, Elisa [1 ]
Borghi, Claudio [1 ]
Cicero, Arrigo Francesco Giuseppe [1 ]
机构
[1] Alma Mater Studiorum Univ Bologna, Med & Surg Sci Dept, Hypertens & Cardiovasc Risk Res Unit, I-40100 Bologna, Italy
关键词
butyrate; clinical trial; dietary supplement; NAFLD; postbiotics; DISEASE; MICROBIOME; KINASE; INDEX;
D O I
10.3390/nu16152454
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Postbiotics could exert different metabolic activities in animal models of non-alcoholic fatty liver disease (NAFLD) and in humans affected by metabolic syndrome. This is a randomized, double-blind, placebo-controlled, parallel-group clinical trial that enrolled a sample of 50 Caucasian healthy individuals with NAFLD, defined as liver steatosis, and metabolic syndrome. After a 4-week run-in, the enrolled individuals were randomized to take a food for special medical purposes with functional release, one tablet a day, containing calcium butyrate (500 mg/tablet), zinc gluconate (zinc 5 mg/tablet), and vitamin D3 (500 IU/tablet), or an identical placebo for 3 months. Liver and metabolic parameters were measured at baseline and at the end of the study. No subject experienced any adverse events during the trial. In both groups, a significant decrease in total cholesterol (TC) and triglycerides (TG) plasma levels was observed at the randomization visit vs. pre-run-in visit (p < 0.05). Regarding liver parameters, after treatment, the fatty liver index (FLI) improved significantly vs. baseline values (p < 0.05) and vs. placebo group (p < 0.05) in the active treatment group, and the hepatic steatosis index (HSI) improved significantly vs. baseline values (p < 0.05). Moreover, after active treatment, TC, TG, and gamma-glutamyl transferase (gGT) improved significantly vs. baseline values (p < 0.05), and TC and TG improved vs. placebo group (p < 0.05), as well. In the placebo group, liver parameters remained unchanged after treatment; only TG improved significantly vs. baseline values (p < 0.05). In our study, we observed that the butyrate-based formula improved FLI and plasma lipid patterns in individuals affected by liver steatosis and metabolic syndrome.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Melatonin supplementation and the effects on clinical and metabolic status in Parkinson's disease: A randomized, double-blind, placebo-controlled trial
    Kakhaki, Reza Daneshvar
    Ostadmohammadi, Vahidreza
    Kouchaki, Ebrahim
    Aghadavod, Esmat
    Bahmani, Fereshteh
    Tamtaji, Omid Reza
    Reiter, Russel J.
    Mansournia, Mohammad Ali
    Asemi, Zatollah
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2020, 195
  • [32] Effect of intranasal oxytocin on alcohol withdrawal syndrome: A randomized placebo-controlled double-blind clinical trial
    Melby, Katrine
    Grawe, Rolf W.
    Aamo, Trond O.
    Salvesen, Oyvind
    Spigset, Olav
    DRUG AND ALCOHOL DEPENDENCE, 2019, 197 : 95 - 101
  • [33] Evaluation of a Crataegus-Based Multiherb Formula for Dyslipidemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Hu, Miao
    Zeng, Weiwei
    Tomlinson, Brian
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2014, 2014
  • [34] Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
    Kawut, Steven M.
    Ellenberg, Susan S.
    Krowka, Michael J.
    Goldberg, David
    Vargas, Hugo
    Koch, David
    Sharkoski, Tiffany
    Al-Naamani, Nadine
    Fox, Alyson
    Brown, Robert
    Levitsky, Joshua
    Oh, Jae K.
    Lin, Grace
    Song, Nianfu
    Mottram, Carl
    Doyle, Margaret F.
    Kaplan, David E.
    Gupta, Samir
    Fallon, Michael B.
    LIVER TRANSPLANTATION, 2019, 25 (08) : 1155 - 1164
  • [35] Effect of calcium supplementation on serum cholesterol and blood pressure - A randomized, double-blind, placebo-controlled, clinical trial
    Bostick, RM
    Fosdick, L
    Grandits, GA
    Grambsch, P
    Gross, M
    Louis, TA
    ARCHIVES OF FAMILY MEDICINE, 2000, 9 (01) : 31 - 38
  • [36] Zinc supplementation and the effects on metabolic status in gestational diabetes: A randomized, double-blind, placebo-controlled trial
    Karamali, Maryam
    Heidarzadeh, Zahra
    Seifati, Seyed Morteza
    Samimi, Mansooreh
    Tabassi, Zohreh
    Hajijafari, Mohammad
    Asemi, Zatollah
    Esmaillzadeh, Ahmad
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2015, 29 (08) : 1314 - 1319
  • [37] Effects of Probiotic Supplementation on Metabolic Status in Pregnant Women: a Randomized, Double-blind, Placebo-Controlled Trial
    Jamilian, Mehri
    Bahmani, Fereshteh
    Vahedpoor, Zahra
    Salmani, Ali
    Tajabadi-Ebrahimi, Maryam
    Jafari, Parvaneh
    Dizaji, Shahrzad Hashemi
    Asemi, Zatollah
    ARCHIVES OF IRANIAN MEDICINE, 2016, 19 (10) : 687 - 692
  • [38] Effect of dietary fiber supplementation on blood pressure: A randomized, double-blind, placebo-controlled trial
    He, J
    Streiffer, RH
    Whelton, PK
    CIRCULATION, 2002, 105 (14) : E98 - E99
  • [39] Effect of dietary fiber supplementation on blood pressure: A randomized, double-blind, placebo-controlled trial
    He, J
    Streiffer, RH
    Whelton, PK
    JOURNAL OF HYPERTENSION, 2002, 20 : S334 - S334
  • [40] Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma
    Curiel-Lewandrowski, Clara
    Swetter, Susan M.
    Einspahr, Janine G.
    Hsu, Chiu-Hsieh
    Nagle, Ray
    Sagerman, Paul
    Tangrea, Joseph
    Parnes, Howard
    Alberts, David S.
    Chow, Hsiao-Hui
    CANCER, 2012, 118 (23) : 5848 - 5856